MENINGOCOCCAL VACCINE PRESCRIBER ORDER FORM  Patient Name: Date of Birth: Gender:  Address:  Phone: Height:   inches   cm   Weight:   lbs    Clinical Information  Primary Diagnosis Description: Encounter for immunization ICD-10 Code: Z23  Meningococcal Vaccine Prescription  MENINGOCOCCAL VACCINATIONS ARE INDICATED FOR PATIENTS, INCLUDING PEOPLE OVER 25 YEARS OF AGE, WHEN ON A COMPLEMENT INHIBITOR TREATI  Option 1: MenACWY (2 dose series) AND MenB (3 dose series)  ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES  Meningococcal Groups (MenACWY) Meningococcal Groups (MenB)	
Address:  Phone:  Clinical Information  Primary Diagnosis Description: Encounter for immunization  Meningococcal Vaccine Prescription  MENINGOCOCCAL VACCINATIONS ARE INDICATED FOR PATIENTS, INCLUDING PEOPLE OVER 25 YEARS OF AGE, WHEN ON A COMPLEMENT INHIBITOR TREATION OPTION 1: MenACWY (2 dose series) AND MenB (3 dose series)  ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES	
Phone:  Clinical Information  Primary Diagnosis Description: Encounter for immunization  Meningococcal Vaccine Prescription  MENINGOCOCCAL VACCINATIONS ARE INDICATED FOR PATIENTS, INCLUDING PEOPLE OVER 25 YEARS OF AGE, WHEN ON A COMPLEMENT INHIBITOR TREATION ON Its Menacoma (2 dose series) AND Menb (3 dose series)  ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES	
Clinical Information  Primary Diagnosis Description: Encounter for immunization  Meningococcal Vaccine Prescription  MENINGOCOCCAL VACCINATIONS ARE INDICATED FOR PATIENTS, INCLUDING PEOPLE OVER 25 YEARS OF AGE, WHEN ON A COMPLEMENT INHIBITOR TREATION OPtion 1: MenACWY (2 dose series) AND MenB (3 dose series)  ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES	
Primary Diagnosis Description: Encounter for immunization  Meningococcal Vaccine Prescription  MENINGOCOCCAL VACCINATIONS ARE INDICATED FOR PATIENTS, INCLUDING PEOPLE OVER 25 YEARS OF AGE, WHEN ON A COMPLEMENT INHIBITOR TREATION OPTION 1: MenACWY (2 dose series) AND MenB (3 dose series)  ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES	<b>JENT</b>
Meningococcal Vaccine Prescription  MENINGOCOCCAL VACCINATIONS ARE INDICATED FOR PATIENTS, INCLUDING PEOPLE OVER 25 YEARS OF AGE, WHEN ON A COMPLEMENT INHIBITOR TREATION OPTION 1: MenACWY (2 dose series) AND MenB (3 dose series)  ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES	/ENT
MENINGOCOCCAL VACCINATIONS ARE INDICATED FOR PATIENTS, INCLUDING PEOPLE OVER 25 YEARS OF AGE, WHEN ON A COMPLEMENT INHIBITOR TREATION OPTION 1: MenACWY (2 dose series) AND MenB (3 dose series)  ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES	/ENT
☐ Option 1: MenACWY (2 dose series) AND MenB (3 dose series) ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES	<b>VENIT</b>
ONE (1) REQUIRED FROM EACH GROUP FOR EACH SERIES	nLIVI.
, , ,	
Choose Brand	
☐ Menveo OR ☐ Menquadfi ☐ Bexsero OR ☐ Trumenba	
Inject MenACWY vaccine 0.5 mL IM x 1 at day 0 Inject MenB vaccine 0.5 mL IM x 1 at day 0	
2 <sup>nd</sup> Dose in Series Inject MenACWY vaccine 0.5 mL IM x 1 (8 weeks after day 0)  Inject MenB vaccine 0.5 mL IM x 1 (1-2 months after day 0)	
3rd Dose in Series N/A Inject MenB vaccine 0.5 mL IM x 1 (6 months after day 0)	
☐ Option 2: Pentavalent (2-3 dose series)	
Meningococcal Groups (MenABCWY)  Meningococcal Groups (MenABCWY)	
☐ Penbraya - ☐ 2 Dose or ☐ 3 Dose ☐ Penmenvy - ☐ 2 Dose or ☐ 3 Dose	
2 DOSE SERIES: 2 DOSE SERIES:	
1) Inject Penbraya vaccine 0.5 mL IM x 1 at day 0 2) Inject Penbraya vaccine 0.5 mL IM x 1 at day 0 2) Inject Penbraya vaccine 0.5 mL IM x 1 (6 months after day 0) 2) Inject Penmenvy vaccine 0.5 mL IM x 1 (6 months after day 0)	
3 DOSE SERIES:  3 DOSE SERIES:	
1) Inject Penbraya vaccine 0.5 mL IM x 1 at day 0  1) Inject Penmenvy vaccine 0.5 mL IM x 1 at day 0	
2) Inject MenACWY vaccine 0.5 mL IM x 1 (8 weeks after day 0)  Menveo OR Menquadfi  2) Inject Menveo vaccine 0.5 mL IM x 1 (8 weeks after day 0)  And	
And Inject Bexsero vaccine 0.5 mL IM x 1 (1-2 months after day 0)	
Inject <b>Trumenba</b> vaccine 0.5 mL IM x 1 (1-2 months after day 0)  3) Inject <b>Trumenba</b> vaccine 0.5 mL IM x 1 (6 months after day 0)  3) Inject <b>Trumenba</b> vaccine 0.5 mL IM x 1 (6 months after day 0)	
☐ Option 3: Booster Dose	
☐ Menveo OR ☐ Menquadfi ☐ Bexsero OR ☐ Trumenba ☐ Penbraya or ☐ Penmenvy	
Inject MenACWY vaccine 0.5 mL IM x1 (Booster)  Inject MenB vaccine 0.5 mL IM x 1 (Booster)  Inject MenACWY vaccine 0.5 mL IM x 1 (Booster)  Inject MenACWY vaccine 0.5 mL IM x 1 (Booster)  Inject MenACWY vaccine 0.5 mL IM x 1 (Booster)	,
MenACWY- every 5 years while on complement inhibitors  MenB: 1 year after initial series then every 2-3 years while on complement inhibitor  Use only when MenACWY and MenB are indicated at the same visit.	ated
Trumenba must be the initial series for Penbr  Bexsero must be the initial series for Penmen	
Ancillary Orders	y.
Anaphylaxis Kit	
Required per Option Care Health policy. The following items will be dispensed:	
☑ Diphenhydramine 50 mg/mL 1 mL vial x 1. Inject 25 mg IM PRN for allergic reaction. May repeat x 1 dose in 15 min PRN if no improve	ement
<ul> <li>✓ 0.9% Sodium Chloride 500 mL bag x 1. Infuse 500 mL IV at KVO rate PRN anaphylaxis.</li> <li>✓ Epinephrine 0.3 mg (&gt; 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (&lt; 15 kg) SubQ or IM x 1; repeat x 1 in 5 to 15 min PRN.</li> </ul>	
Skilled Nursing to establish peripheral IV access as needed to manage anaphylaxis. Skilled nurse to administer vaccination series.	
If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatments	ent,
and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.	
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.	
Prescriber Signature: Date:	
Prescriber Information	
Prescriber Name: Phone: Fax:	
Address: NPI:	
City, State: Zip: Office Contact:	
City, State: Zip: Office Contact:  Fax completed form, insurance information, and clinical documentation to: (800) 420-5150	

authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agen responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.